BiotechTube
Matrubials

Matrubials

San Diego, United States· Est.
matrubials.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.8M

Overview

Matrubials is a private, preclinical-stage biotech spin-off from UC Davis, founded in 2016 and based in San Diego, CA. The company leverages an AI-enabled platform to discover and develop antimicrobial peptides derived from milk, aiming to provide selective and safe alternatives to traditional antibiotics. Its lead program targets Bacterial Vaginosis (BV), a condition with significant unmet need and long-term health complications for women. Matrubials represents a novel approach to infectious disease by mining nature's evolutionary solutions for new therapeutic candidates.

Infectious DiseaseWomen's Health

Technology Platform

AI-enabled platform for discovering and validating antimicrobial peptides derived from mammalian milk.

Funding History

2
Total raised:$2.8M
Grant$300K
Seed$2.5M

Opportunities

The significant unmet need in Bacterial Vaginosis, a condition with high recurrence rates and serious long-term health complications, presents a clear initial market.
Furthermore, the global antimicrobial resistance crisis creates a massive long-term opportunity for the company's platform to develop novel, selective antibacterial therapies for a wide range of infections.

Risk Factors

As a preclinical company, Matrubials faces high technical risk in successfully translating its discoveries into safe and effective human therapies.
The competitive landscape for microbiome-based therapies is intensifying, and the business model for novel anti-infectives is challenged by pricing pressures and stewardship concerns.

Competitive Landscape

In the Bacterial Vaginosis space, competition includes generic antibiotics and companies developing live biotherapeutic products (e.g., Lactin-V from Osel). More broadly, Matrubials competes in the novel antimicrobial space with other companies developing peptides, phage therapies, and other modalities to address antibiotic resistance.

More companies in Small Molecule Drugs →More companies in United States →